Publication Name	World Journal of Hepatology
Manuscript ID	71625
Country	India

Received	2021-09-15 12:08
Peer-Review Started	2021-09-15 12:10
To Make the First Decision
Return for Revision	2021-10-18 08:17
Revised	2021-10-22 17:40
Second Decision	2022-02-08 05:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-02-10 16:46
Articles in Press	2022-02-10 16:46
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-01-28 00:59
Typeset the Manuscript	2022-02-15 09:26
Publish the Manuscript Online	2022-02-22 09:25

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	COVID-19 and liver disease: Are we missing something?
Manuscript Source	Invited Manuscript
All Author List	Tarana Gupta
ORCID	Author(s) ORCID Number Tarana Gupta http://orcid.org/0000-0003-3453-2040
Funding Agency and Grant Number
Corresponding Author	Tarana Gupta, Doctor, MBBS, MD, Professor, Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Medical Mor, Rohtak 124001, Haryana, India. taranagupta@gmail.com
Key Words	COVID-19; Liver disease; Transaminases; Non-alcoholic fatty liver disease; Hepatocytes; Cholangiocytes
Core Tip	The presence of angiotensin converting enzyme 2 receptors in liver endothelial cells make it susceptible to severe acute respiratory syndrome coronavirus 2 injury. The authors have suggested raised aspartate aminotransferase (AST) levels in almost a third of non-survivors along with high AST/alanine aminotransferase ratio. Considering the presence of AST in organs other than liver like muscle, red blood cells, heart and kidney, makes the interpretation difficult. Additionally, pre-existing non-alcoholic fatty liver disease has also been documented as a risk factor for severe coronavirus disease 2019 (COVID-19) disease. Therefore, more studies are needed for evaluation of AST as a predictive factor for severe COVID-19 disease.
Publish Date	2022-02-22 09:25
Citation	Gupta T. COVID-19 and liver disease: Are we missing something? World J Hepatol 2022; 14(2): 479-481
URL	https://www.wjgnet.com/1948-5182/full/v14/i2/479.htm
DOI	https://dx.doi.org/10.4254/wjh.v14.i2.479

Full Article (PDF)	WJH-14-479.pdf
Full Article (Word)	WJH-14-479.docx
Manuscript File	71625_Auto_Edited-JRF-Filipodia CL.docx
Answering Reviewers	71625-Answering reviewers.pdf
Audio Core Tip	71625-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	71625-Conflict-of-interest statement.pdf
Copyright License Agreement	71625-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	71625-Language certificate.pdf
Peer-review Report	71625-Peer-review(s).pdf
Scientific Misconduct Check	71625-Bing-Fan JR-2.png
Scientific Editor Work List	71625-Scientific editor work list.pdf
CrossCheck Report	71625-CrossCheck report.pdf
CrossCheck Report	71625-CrossCheck.png